NSCLC
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Lilly’s lung cancer drug sees FDA approval
December 17, 2014Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab
Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
BMS lung cancer drug scores in Phase II
October 31, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo
Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
Boehringer lung cancer drug shows survival benefit
June 3, 2014Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer
A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …
AstraZeneca lung cancer data reveals promise
May 15, 2014Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer
AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …
AstraZeneca begins lung cancer trial
May 9, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer
AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …
Lung cancer vaccine dropped
April 2, 2014Research and Development, Sales and Marketing GSK, MAGE-A3, NSCLC, Vaccine, lung cancer, magrit
GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now …
Pfizer’s Xalkori impresses in new setting
March 26, 2014Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer
Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …
Endocyte lung cancer drug shows promise
March 24, 2014Research and Development, Sales and Marketing Endocyte, MSD, NSCLC, lung cancer, vintafolide
Endocyte and partner MSD have released positive mid-stage trial results for their investigational lung cancer drug vintafolide. The treatment met …
GSK cancer vaccine fails again
March 20, 2014Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma
GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials. The …
Boehringer’s first cancer drug gains NICE yes
March 17, 2014Sales and Marketing Boehringer, Cancer, NICE, NSCLC, afatinib, giotrif
NICE is recommending that Boehringer Ingelheim’s first oncology treatment Giotrif be funded by the NHS. The new final draft guidance …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
